130 related articles for article (PubMed ID: 22302034)
1. Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.
Portelius E; Gustavsson MK; Zetterberg H; Andreasson U; Blennow K
Neurodegener Dis; 2012; 10(1-4):138-40. PubMed ID: 22302034
[TBL] [Abstract][Full Text] [Related]
2. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
[TBL] [Abstract][Full Text] [Related]
4. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.
Du P; Wood KM; Rosner MH; Cunningham D; Tate B; Geoghegan KF
J Pharmacol Exp Ther; 2007 Mar; 320(3):1144-52. PubMed ID: 17202404
[TBL] [Abstract][Full Text] [Related]
5. Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry.
Sarasa L; Allué JA; Pesini P; González-Martínez A; Sarasa M
Neurobiol Aging; 2013 Sep; 34(9):2125-32. PubMed ID: 23582658
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
Maddalena AS; Papassotiropoulos A; Gonzalez-Agosti C; Signorell A; Hegi T; Pasch T; Nitsch RM; Hock C
Neurodegener Dis; 2004; 1(4-5):231-5. PubMed ID: 16908995
[TBL] [Abstract][Full Text] [Related]
7. Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment.
Portelius E; Mattsson N; Andreasson U; Blennow K; Zetterberg H
Curr Pharm Des; 2011; 17(25):2594-602. PubMed ID: 21728980
[TBL] [Abstract][Full Text] [Related]
8. A novel pathway for amyloid precursor protein processing.
Portelius E; Price E; Brinkmalm G; Stiteler M; Olsson M; Persson R; Westman-Brinkmalm A; Zetterberg H; Simon AJ; Blennow K
Neurobiol Aging; 2011 Jun; 32(6):1090-8. PubMed ID: 19604603
[TBL] [Abstract][Full Text] [Related]
9. Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
Portelius E; Zhang B; Gustavsson MK; Brinkmalm G; Westman-Brinkmalm A; Zetterberg H; Lee VM; Trojanowski JQ; Blennow K
Neurodegener Dis; 2009; 6(5-6):258-62. PubMed ID: 19955704
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
11. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients.
Bibl M; Gallus M; Welge V; Esselmann H; Wiltfang J
J Alzheimers Dis; 2012; 29(4):809-16. PubMed ID: 22460324
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
13. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
15. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
Gelfanova V; Higgs RE; Dean RA; Holtzman DM; Farlow MR; Siemers ER; Boodhoo A; Qian YW; He X; Jin Z; Fisher DL; Cox KL; Hale JE
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):149-58. PubMed ID: 17584762
[TBL] [Abstract][Full Text] [Related]
18. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
[TBL] [Abstract][Full Text] [Related]
19. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
20. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E
Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
